76 related articles for article (PubMed ID: 1281430)
1. The interaction of a glycosaminoglycan, heparin, with HIV-1 major envelope glycoprotein.
Mbemba E; Czyrski JA; Gattegno L
Biochim Biophys Acta; 1992 Dec; 1180(2):123-9. PubMed ID: 1281430
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate binding properties of the envelope glycoproteins of human immunodeficiency virus type 1.
Haidar M; Seddiki N; Gluckman JC; Gattegno L
Glycoconj J; 1992 Dec; 9(6):315-23. PubMed ID: 1284814
[TBL] [Abstract][Full Text] [Related]
3. Molecular interaction between HIV-1 major envelope glycoprotein and dextran sulfate.
Mbemba E; Chams V; Gluckman JC; Klatzmann D; Gattegno L
Biochim Biophys Acta; 1992 Jan; 1138(1):62-7. PubMed ID: 1371075
[TBL] [Abstract][Full Text] [Related]
4. alpha 1-Acid glycoprotein binds human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein via N-linked glycans.
Rabehi L; Ferriere F; Saffar L; Gattegno L
Glycoconj J; 1995 Feb; 12(1):7-16. PubMed ID: 7795416
[TBL] [Abstract][Full Text] [Related]
5. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
[TBL] [Abstract][Full Text] [Related]
6. Interactions of HIV-1 and HIV-2 envelope glycoproteins with sulphated polysaccharides and mannose-6-phosphate.
Mbemba E; Gluckman JC; Gattegno L
Glycobiology; 1994 Feb; 4(1):13-21. PubMed ID: 8186546
[TBL] [Abstract][Full Text] [Related]
7. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva.
Su H; Boackle RJ
Mol Immunol; 1991 Aug; 28(8):811-7. PubMed ID: 1875953
[TBL] [Abstract][Full Text] [Related]
8. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
9. Interactions of HIV-1 envelope glycoproteins with derivatized dextrans.
Carré V; Mbemba E; Letourneur D; Jozefonvicz J; Gattegno L
Biochim Biophys Acta; 1995 Feb; 1243(2):175-80. PubMed ID: 7532999
[TBL] [Abstract][Full Text] [Related]
10. Complement activation by gp160 glycoprotein of HIV-1.
Thieblemont N; Haeffner-Cavaillon N; Weiss L; Maillet F; Kazatchkine MD
AIDS Res Hum Retroviruses; 1993 Mar; 9(3):229-33. PubMed ID: 8471312
[TBL] [Abstract][Full Text] [Related]
11. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.
Lederman S; Gulick R; Chess L
J Immunol; 1989 Aug; 143(4):1149-54. PubMed ID: 2545782
[TBL] [Abstract][Full Text] [Related]
12. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein.
Fenouillet E; Gluckman JC
J Gen Virol; 1991 Aug; 72 ( Pt 8)():1919-26. PubMed ID: 1678778
[TBL] [Abstract][Full Text] [Related]
13. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160.
Tacket CO; Baqar S; Munoz C; Murphy JR
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):535-42. PubMed ID: 2187503
[TBL] [Abstract][Full Text] [Related]
14. Conglutinin binds the HIV-1 envelope glycoprotein gp 160 and inhibits its interaction with cell membrane CD4.
Andersen O; Sørensen AM; Svehag SE; Fenouillet E
Scand J Immunol; 1991 Jan; 33(1):81-8. PubMed ID: 1996409
[TBL] [Abstract][Full Text] [Related]
15. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4.
Harrop HA; Rider CC
Glycobiology; 1998 Feb; 8(2):131-7. PubMed ID: 9451022
[TBL] [Abstract][Full Text] [Related]
16. Lectin-carbohydrate interactions and infectivity of human immunodeficiency virus type 1 (HIV-1).
Gattegno L; Ramdani A; Jouault T; Saffar L; Gluckman JC
AIDS Res Hum Retroviruses; 1992 Jan; 8(1):27-37. PubMed ID: 1736938
[TBL] [Abstract][Full Text] [Related]
17. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
[TBL] [Abstract][Full Text] [Related]
18. The envelope of HIV-1 as a key component to infectivity.
Buchbinder A
Prog AIDS Pathol; 1990; 2():1-11. PubMed ID: 2103853
[No Abstract] [Full Text] [Related]
19. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
Kelker HC; Schlesinger D; Valentine FT
J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
[TBL] [Abstract][Full Text] [Related]
20. Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of N-glycans.
Bahraoui E; Benjouad A; Guetard D; Kolbe H; Gluckman JC; Montagnier L
AIDS Res Hum Retroviruses; 1992 May; 8(5):565-73. PubMed ID: 1515210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
